

FISCAL IMPLICATIONS

There are no significant fiscal implications.

SIGNIFICANT ISSUES

Currently only medical physicians may approve the prescriptive protocol for pharmacist clinician. This makes clear that a doctor of osteopathy may also be the approving entity for pharmacist clinician’s prescriptive protocol.

According to RLD, the Board of Osteopathic Medical Examiners has not been able to adopt rules concerning the guidelines and protocol for practitioners and pharmacist clinicians because there are no statutes in the Osteopathic Medicine and Surgery Act that support it.

TECHNICAL ISSUES

Page 5, lines 20-25 the reference to Subsection C of 6-11B-2 NMSA 1978 may be a typo. There is no statute titled 6-11B-2 NMSA 1978. Also, if the reference was meant to read Subsection C of Section 61-11B-2 NMSA 1978, that subsection defines “dangerous drug”. However, Subsection D of 61-11B-2 NMSA 1978 defines “guidelines or protocol”.

CE/km